How much does Sotorasib cost in Laos?

Sotorasib (Sotorasib) is a new type of anti-cancer drug that belongs to KRAS The category of G12Cinhibitors is used to treat patients with KRAS geneG12C mutations in non-small cell lung cancer (NSCLC). KRASgene mutations are common in a variety of cancers, especially in NSCLC, so the development of sotoracib fills the gap in the treatment of this gene mutation.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive.

The cheaper ones are the generic drugs sold abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan, which is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

Sotoracib is unique in that it is the first therapeutic to directly intervenein the KRAS G12C mutation. KRASgene is a key gene that regulates cell growth and differentiation. When its G12C site is mutated, cells will be unable to regulate growth normally, thus promoting the occurrence of cancer. By specifically inhibiting the KRAS G12C mutation, sotoracib effectively blocks the growth signaling pathway of cancer cells, thereby potentially inhibiting the development of tumors.

Clinical trial results show that sotorasiib exhibits significant efficacy in some KRAS G12C mutated NSCLC patients, bringing new treatment options to this patient group. The development of this drug represents a major advance in the field of cancer treatment, because in the past, scientists have considered directly interfering with the KRAS gene to be an extremely challenging task.

Patients need to be under the supervision of a doctor when using sotoraxib, and use the drug correctly according to the doctor's recommendations. The advent of sotorasiib provides a new treatment option that is expected to improve survival for patients with NSCLC suffering from KRAS G12C mutations, and also brings new hope to the field of tumor treatment.